McGinley Kathleen F, Sun Xizi, Howard Lauren E, Aronson William J, Terris Martha K, Kane Christopher J, Amling Christopher L, Cooperberg Matthew R, Freedland Stephen J
Division of Urology, Department of Surgery, Duke University, Durham, North Carolina, USA.
Division of Urology, Veterans Affairs Medical Center, Durham, North Carolina, USA.
Int J Urol. 2017 Aug;24(8):611-617. doi: 10.1111/iju.13387. Epub 2017 Jun 6.
To examine if there is a subset of men with grade group 2 prostate cancer who could be potential candidates for active surveillance.
We used the Shared Equal Access Regional Cancer Hospital database to identify 776 men undergoing radical prostatectomy from 2006 to 2015 with >8 biopsy cores obtained and complete information. We compared men who fulfilled low-risk disease criteria (clinical stage T1c/T2a; grade group 1; prostate-specific antigen ≤10 ng/mL) with the exception of grade group 2 versus men who met all three low-risk criteria. Logistic regression was used to test the association between grade group and radical prostatectomy pathological features. Biochemical recurrence was examined using Cox models. To examine whether there was a subset of men with low-volume grade group 2 with comparable outcomes to low-risk men, we repeated all analyses limiting the percentage of positive cores in the grade group 2 group to ≤33%, and positive cores to ≤4, ≤3 or ≤2.
Grade group 2 low-risk men had increased risk of pathological grade group 3 or higher (P < 0.001), extraprostatic extension (P < 0.001), seminal vesicle invasion (P < 0.001) and higher risk of biochemical recurrence (hazard ratio = 1.76, P = 0.006). Using increasingly strict definitions of low-volume disease, at ≤2 positive cores there was no difference in adverse pathology between groups (all P > 0.2), except higher pathological grade group (P = 0.006). Biochemical recurrence was similar in men in grade group 1 and grade group 2 (hazard ratio = 1.24; P = 0.529).
Among men with prostate-specific antigen ≤10 ng/mL and clinical stage T1c/T2a, those in grade group 2 with ≤2 total positive cores have similar rates of adverse pathology and biochemical recurrence as men with grade group 1.
研究是否存在一组2级前列腺癌男性患者有可能成为积极监测的潜在对象。
我们利用共享平等访问区域癌症医院数据库,识别出2006年至2015年间接受根治性前列腺切除术的776名男性患者,这些患者获取了超过8个活检样本且信息完整。我们将符合低风险疾病标准(临床分期T1c/T2a;1级组;前列腺特异性抗原≤10 ng/mL)但除外2级组的男性与符合所有三项低风险标准的男性进行比较。采用逻辑回归分析来检验2级组与根治性前列腺切除术后病理特征之间的关联。使用Cox模型检查生化复发情况。为了研究是否存在一组低体积2级组男性患者,其结果与低风险男性相当,我们重复了所有分析,将2级组中阳性样本的百分比限制在≤33%,且阳性样本数限制在≤4、≤3或≤2。
2级低风险男性患者出现病理3级或更高分级(P < 0.001)、前列腺外侵犯(P < 0.001)、精囊侵犯(P < 0.001)的风险增加,且生化复发风险更高(风险比 = 1.76,P = 0.006)。采用对低体积疾病越来越严格的定义,当阳性样本数≤2时,除了更高的病理分级组(P = 0.006)外,两组之间的不良病理情况无差异(所有P > 0.2)。1级组和2级组男性的生化复发情况相似(风险比 = 1.24;P = 0.529)。
在前列腺特异性抗原≤10 ng/mL且临床分期为T1c/T2a的男性患者中,2级组且总阳性样本数≤2的患者与1级组患者的不良病理发生率和生化复发率相似。